Cartesian Therapeutics, Inc. (United States)

The myasthenia gravis market across seven major markets is projected to grow from $6.1 billion in 2024 to $10.3 billion by 2034, representing a 5.3% compound annual growth rate.

The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.

Cartesian Therapeutics secured FDA agreement for Phase 3 trial of Descartes-08 in myasthenia gravis, potentially leading to BLA submission.

Insulin icodec, a once-weekly basal insulin analog, demonstrated positive safety and efficacy in phase 3 trials for type 2 diabetes, potentially reducing injection burden and improving adherence.

Cartesian Therapeutics is set to begin Phase 3 AURORA trial of Descartes-08 for myasthenia gravis in the first half of 2025.

UChicago Medicine launched a Phase 2 clinical trial to explore CAR T-cell therapy for systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis.

Cartesian Therapeutics is set to begin a Phase 3 trial (AURORA) for Descartes-08, an mRNA CAR-T therapy, in patients with acetylcholine receptor autoantibody positive (AChR Ab+) myasthenia gravis (MG).

Cartesian Therapeutics received FDA agreement under the Special Protocol Assessment for its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.

The FDA has granted Rare Pediatric Disease Designation to Cartesian Therapeutics' Descartes-08 for treating juvenile dermatomyositis (JDM).

Cartesian Therapeutics' Descartes-08 met the primary endpoint in a Phase 2b trial for myasthenia gravis, demonstrating statistically significant improvement in MGC scores.